Document Detail


Enhanced cardiovascular protective effects of valsartan in high-risk hypertensive patients with left ventricular hypertrophy--sub-analysis of the KYOTO HEART study.
MedLine Citation:
PMID:  21436597     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The objective of the present study was to examine whether baseline electrocardiographically diagnosed left ventricular hypertrophy (ECG-LVH) influenced the angiotensin II receptor blocker (ARB) valsartan add-on effects on the cardio-cerebrovascular morbidity and mortality in the high-risk hypertensive patients who participated in the KYOTO HEART Study.
METHODS AND RESULTS: The primary endpoint was the same as in the main study: a composite of defined cardiovascular and cerebrovascular events. The median follow-up period was 3.27 years. The study group was divided into 2 groups according to the presence of ECG-LVH: with LVH, n=803; without LVH, n=2,228. The primary endpoint events occurred more frequently in patients with LVH than in patients without LVH (9.3% vs. 7.3%; hazard ratio [HR], 1.33; 95% confidence interval [CI]: 1.01-1.75). Valsartan add-on significantly decreased the occurrence of primary endpoint events in both LVH-positive patients (5.8% vs. 12.9%; HR, 0.45; 95%CI: 0.28-0.72) and LVH-negative patients (5.5% vs. 9.2%; HR, 0.59; 95%CI: 0.44-0.81) compared with non-ARB treatment. The reduction in combined cardiovascular events (composite of acute myocardial infarction, angina pectoris, and heart failure) due to valsartan treatment in patients with LVH was significantly larger than that in patients without LVH (P<0.0001). Changes in blood pressure during the follow-up period did not differ significantly among the study subgroups.
CONCLUSIONS: High-risk hypertensive patients with ECG-LVH might gain more cardiovascular benefits from valsartan add-on treatment, compared with patients without ECG-LVH.
Authors:
Jun Shiraishi; Takahisa Sawada; Shinzo Kimura; Hiroyuki Yamada; Hiroaki Matsubara;
Related Documents :
8571877 - Color doppler sonography in graves' disease: value in assessing activity of disease and...
24618287 - Hla-dr typing in polyarticular juvenile idiopathic arthritis: a study from a tertiary c...
6326447 - The presence of autoantibodies directed to thyroid plasma membrane antigens in sera of ...
9177377 - Increased serum concentration of soluble cd30 in patients with graves' disease and hash...
1501047 - Surgical aspects of chronic peritoneal dialysis in the neonate and infant under 1 year ...
23801137 - Clinical features and treatment of multicentric castleman's disease : a retrospective s...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Retracted Publication     Date:  2011-03-19
Journal Detail:
Title:  Circulation journal : official journal of the Japanese Circulation Society     Volume:  75     ISSN:  1347-4820     ISO Abbreviation:  Circ. J.     Publication Date:  2011  
Date Detail:
Created Date:  2011-03-28     Completed Date:  2011-08-12     Revised Date:  2013-03-28    
Medline Journal Info:
Nlm Unique ID:  101137683     Medline TA:  Circ J     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  806-14     Citation Subset:  IM    
Copyright Information:
All rights are reserved to the Japanese Circulation Society.
Affiliation:
Department of Cardiology, Kyoto First Red Cross Hospital, Kyoto 605-0981, Japan. risa11221998@yahoo.co.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angiotensin II Type 1 Receptor Blockers / administration & dosage*,  adverse effects
Electrocardiography
Female
Follow-Up Studies
Humans
Hypertension / diagnosis,  drug therapy*,  mortality
Hypertrophy, Left Ventricular / diagnosis,  drug therapy*,  mortality
Male
Middle Aged
Risk Factors
Tetrazoles / administration & dosage*,  adverse effects
Valine / administration & dosage,  adverse effects,  analogs & derivatives*
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Tetrazoles; 137862-53-4/valsartan; 7004-03-7/Valine
Comments/Corrections
Retraction In:
Shimokawa H. Circ J. 2013;77(2):552b   [PMID:  23358392 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan-...
Next Document:  Significant lowering of plasma ghrelin but not des-acyl ghrelin in response to acute exercise in men...